Research programme: recombinant bioheparin - Acorda Therapeutics

Drug Profile

Research programme: recombinant bioheparin - Acorda Therapeutics

Alternative Names: BioHeparin

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotie Therapies Corp.
  • Class Heparins; Recombinant proteins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 20 Jul 2010 Discontinued - Preclinical for Thrombosis in Finland (unspecified route)
  • 01 Nov 2006 This compound is still in active development
  • 19 Oct 2005 BioTie is seeking partners for the development of this programme (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top